Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib MR vs IR in RA
NCT02281552Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2014
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tofacitinib oral solution in rheumatoid arthritis (RA) (2 arms), sponsored by Pfizer. Primary endpoint: Change From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (C-Reactive Protein [CRP]) at 12 weeks. Started Nov 2014; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02281552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281552.